- Home
- Contributors
- CME Outfitters
CME Outfitters
CME Outfitters is an independent accredited healthcare communications agency providing multidisciplinary continuing medical education content development, production, marketing, accreditation, and project management services to the healthcare industry.
CME by this Contributor
Continuing Medical Education: Psychiatry CME: CME Outfitters: Bipolar Depression: Individualizing Treatment to Prevent Relapse and Recurrence: Online Psychiatry CME: September 10, 2008
- By CME Outfitters
- Published 07/15/2008
- Psychiatry
- Unrated
Bipolar Depression: Individualizing Treatment to Prevent Relapse and Recurrence
CME Outfitters
September 10, 2008
There is an unmet need for acute - and in particular, maintenance - pharmacologic treatments that target bipolar depression. Despite the preponderance of depressive symptoms and episodes (versus manic) over the course of both bipolar I and II disorder, and the more frequent functional impairment associated with bipolar depression, there has been a disproportionate lack of attention paid to establishing effective treatment and management of bipolar depression. This has recently begun to change, however, with the approval and addition of atypical antipsychotics to the arsenal of medications used for bipolar depression.
Recently completed studies and trials in progress are expected to contribute to the growing literature supporting the effectiveness of these types of medications for the treatment of bipolar depression. Clinicians are in urgent need of education and performance improvement in the recognition, diagnosis, and acute and maintenance treatment of bipolar depression. Published treatment guidelines are an adequate framework for developing treatment plans. However, clinicians need additional education on pharmacologic treatments for bipolar depression. In this evidence-based, neuroscienceCME TV activity, experts will provide information on pharmacologic treatments for bipolar depression that will enable participants to integrate these findings into current treatment guidelines to further enhance and maintain good patient outcomes.
CME Outfitters
September 10, 2008
There is an unmet need for acute - and in particular, maintenance - pharmacologic treatments that target bipolar depression. Despite the preponderance of depressive symptoms and episodes (versus manic) over the course of both bipolar I and II disorder, and the more frequent functional impairment associated with bipolar depression, there has been a disproportionate lack of attention paid to establishing effective treatment and management of bipolar depression. This has recently begun to change, however, with the approval and addition of atypical antipsychotics to the arsenal of medications used for bipolar depression.
Recently completed studies and trials in progress are expected to contribute to the growing literature supporting the effectiveness of these types of medications for the treatment of bipolar depression. Clinicians are in urgent need of education and performance improvement in the recognition, diagnosis, and acute and maintenance treatment of bipolar depression. Published treatment guidelines are an adequate framework for developing treatment plans. However, clinicians need additional education on pharmacologic treatments for bipolar depression. In this evidence-based, neuroscienceCME TV activity, experts will provide information on pharmacologic treatments for bipolar depression that will enable participants to integrate these findings into current treatment guidelines to further enhance and maintain good patient outcomes.
Continuing Medical Education: Psychiatry CME: CME Outfitters: The Impact of Adherence on Maintenance Treatment in Schizophrenia: Online Psychiatry CME: August 6, 2008
- By CME Outfitters
- Published 07/11/2008
- Psychiatry
- Unrated
The Impact of Adherence on Maintenance Treatment in Schizophrenia
CME Outfitters
August 6, 2008
Shared decision-making is a vital part of developing a maintenance treatment plan to support remission and long-term functional recovery in patients with schizophrenia. A vital part of this process is the discussion of various medications with respect to safety, side effects, and complexity of regimen. The impact of maintenance pharmacotherapy is often limited due to poor medication adherence and treatment strategies that maximize adherence can improve outcomes. In this patient population, rates of medication nonadherence range from 40-55% and may be even higher in patients with more pronounced deficits, more severe symptoms, higher rates of relapse, and relatively little social support. Evidence-based strategies exist for facilitating adherence; consideration of issues related to adherence during treatment decisionmaking has the potential to reduce relapse and improve outcomes. In this neuroscienceCME TV activity, experts will review the importance of medication adherence to remission and recovery, and will discuss strategies to translate evidence into improved long-term outcomes for their patients.
CME Outfitters
August 6, 2008
Shared decision-making is a vital part of developing a maintenance treatment plan to support remission and long-term functional recovery in patients with schizophrenia. A vital part of this process is the discussion of various medications with respect to safety, side effects, and complexity of regimen. The impact of maintenance pharmacotherapy is often limited due to poor medication adherence and treatment strategies that maximize adherence can improve outcomes. In this patient population, rates of medication nonadherence range from 40-55% and may be even higher in patients with more pronounced deficits, more severe symptoms, higher rates of relapse, and relatively little social support. Evidence-based strategies exist for facilitating adherence; consideration of issues related to adherence during treatment decisionmaking has the potential to reduce relapse and improve outcomes. In this neuroscienceCME TV activity, experts will review the importance of medication adherence to remission and recovery, and will discuss strategies to translate evidence into improved long-term outcomes for their patients.
